# EDGAR Filing Document

**Accession Number:** 0001536196
**File Stem:** 0001213900-25-065120
**Filing Date:** 2025-7
**Character Count:** 4589
**Document Hash:** ea08444aa58d3c70dafb7e536e17ee61
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-065120.hdr.sgml**: 20250905

**ACCESSION NUMBER**: 0001213900-25-065120

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250717

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Can-Fite BioPharma Ltd.
- **CENTRAL INDEX KEY:** 0001536196
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 26 BEN GURION STREET
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5257346
- **BUSINESS PHONE:** 972 39241114

**MAIL ADDRESS:**
- **STREET 1:** 26 BEN GURION STREET
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5257346

July 17, 2025

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences<br> 100 F Street, N.E.<br> Washington, D.C. 20549

Attention: Tracie Mariner <br> Jenn Do

---

| | |
|:---|:---|
| **Re:** | **Can-Fite BioPharma Ltd.**<br> **Form 20-F for Fiscal Year Ended December 31, 2024**<br> **File No. 001-36203** |

---

Dear Ms. Mariner and Ms. Do:

On behalf of Can-Fite BioPharma Ltd. (the "**Company**"), we are writing to submit the Company's response to the comment of the staff (the "**Staff**") of the Division of Corporation Finance of the Securities and Exchange Commission (the "**Commission**") dated June 17, 2025, relating to the above referenced Annual Report on Form 20-F (File No. 001-36203) filed by the Company on April 14, 2025 (the "**Form 20-F**").

For ease of review, we have set forth below the numbered comment of your letter and the Company's response thereto. Capitalized terms used herein but not defined herein have the meanings given to such terms in the Form 20-F.

<u>Form 20-F for Fiscal Year Ended December 31, 2024</u>

<u>Operating and Financial Review and Prospects</u>

<u>Research and Development, page 97</u>

1. **We note from your pipeline chart, on page 47, that Piclidenoson and Namodenoson are each in clinical development for two or more indications. In future filings, please provide revised disclosure in your table of gross direct project costs to include, during each year presented, the costs incurred for each of your main projects by indication. If you do not track your research and development costs by indication, disclose that fact, and explain why not. Include draft disclosure with your response.**

<u>Response</u>: In response to the Staff's comment, the Company confirms that, in future filings, it will provide revised disclosure in its table of gross direct project costs to include, during each year presented, the costs incurred for each of its main projects by indication. A draft of the revised pipeline chart that the Company plans to include in future filings is set forth below.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **($ in thousands)** | **($ in thousands)** | **($ in thousands)** | | |
|  | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | | |
|  | **2022** | **2023** | **2024** | **[Interim Period** **to be**<br> **Included**<br>**if Applicable]** | **Costs<br> Since**<br>**Project**<br>**Inception** |
| Piclidenoson |  |  |  |  |  |
| - Psoriasis | 2354 | 1444 | 550 |  |  |
| - Lowe syndrome |  |  |  |  |  |
| - Dogs osteoarthritis |  |  |  |  |  |
| - Pre clinical & API | 436 | 27 | 10 |  |  |
|  | **2790** | **1471** | **560** |  |  |
| Namodenoson |  |  |  |  |  |
| - Liver cancer | 1274 | 1755 | 1990 |  |  |
| - Pancreatic cancer |  |  | 169 |  |  |
| - MASH | 827 | 1225 | 1230 |  |  |
| - Pre clinical & API | 1282 | 9 | - |  |  |
|  | **3883** | **2989** | **3389** |  |  |
| CF602 (erectile dysfunction) | **6** | **-** | **-** |  |  |
| Other projects | - | - | - |  |  |
| Total gross direct project costs <sup>(1)</sup> | 6179 | 4460 | 3949 |  |  |

---

(1) Does not include indirect project
costs and overhead, such as payroll and related expenses (including stock-based compensation), facilities, depreciation and impairment
of intellectual property, which are included in total research and development expenses in our financial statements.

Please contact me at +972 39241114 if you have any questions or require any additional information in connection with this letter or the Company's submission of its Form 20-F.

---

| |
|:---|
| Sincerely, |
| /s/ Motti Farbstein |
| Chief Executive Officer and Chief Financial Officer |

---